Issue 33, 2017

Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells

Abstract

Conventional chemotherapy drugs such as paclitaxel (PTX) can effectively inhibit tumor growth by killing the majority of the proliferating cancer cells; however, it also results in multi-drug resistance (MDR) and facilitates the conversion of non-cancer stem cells (non-CSCs) to cancer stem cells (CSCs), which are considered the reason for chemotherapy resistance, relapse, and metastasis. Thus, exploring combination therapy with multiple chemotherapeutics is considered as a promising approach for simultaneously eliminating CSCs and non-CSCs. Here, we fabricated a bCSC (breast cancer stem cell)-targeting co-delivery system (HA-hybrid NPs) by attaching a lipoid (HA-HDA) to the surface of hydrophobic PLGA nanoparticles to co-deliver the widely used chemotherapy agent, PTX, and the selective inhibitor of CSCs, curcumin (CUR). This co-delivery system was capable of targeting bCSCs via an interaction between HA and the CD44 receptor on the membrane of bCSCs, and it could efficiently eliminate the bCSC population, decrease the mammosphere formation of bCSCs, and inhibit the migration of bCSCs. Most importantly, HA-hybrid co-delivered NPs exhibited enhanced anti-tumor efficacy by synergistically inhibiting the growth of both non-bCSCs and bCSCs on MCF7 xenografted tumor models. Taken together, the results of this study demonstrate that this bCSC-targeted HA-hybrid NP provides a potential strategy for enhancing breast cancer therapeutic efficiency.

Graphical abstract: Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells

Supplementary files

Article information

Article type
Paper
Submitted
05 Jun 2017
Accepted
20 Jul 2017
First published
20 Jul 2017

J. Mater. Chem. B, 2017,5, 6762-6775

Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells

Z. Yang, N. Sun, R. Cheng, C. Zhao, J. Liu and Z. Tian, J. Mater. Chem. B, 2017, 5, 6762 DOI: 10.1039/C7TB01510K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements